UK's competition watchdog flags concerns over Demant, Cochlear deal

Cochlear Ltd COH:

• UK'S COMPETITION AND MARKETS AUTHORITY SAYS MERGER OF 2 LEADING PROVIDERS OF HEARING IMPLANTS COULD LEAD TO HIGHER PRICES FOR NHS, AND REDUCED QUALITY AND SLOWER INNOVATION FOR UK PATIENTS WHO RELY ON THESE LIFE-CHANGING DEVICES.

• UK'S COMPETITION AND MARKETS AUTHORITY SAYS IS CONCERNED THAT COCHLEAR'S PROPOSED PURCHASE OF OTICON MEDICAL - HEARING IMPLANT DIVISION OF DEMANT -WOULD HAVE A NEGATIVE IMPACT ON PATIENTS WHO NEED HEARING IMPLANTS

• UK'S COMPETITION AND MARKETS AUTHORITY SAYS COCHLEAR AND DEMANT NOW HAVE UNTIL 13 DECEMBER 2022 TO ADDRESS CMA'S CONCERNS THROUGH OFFER OF UNDERTAKINGS.